 Good morning, everyone, and welcome to the Oyster Point conference call to discuss top-line results for the Phase 3 ONSET-2 clinical trial in patients with dry eye disease. This morning, we issued two press releases, one covering the top-line results from the Phase 3 ONSET-2 trial, as well as the companys first-quarter 2020 financial results for the three months ended March 31, 2020. 